

# Financial Tear Sheet

## Corporate Profile

## Investors

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, immuno-oncology agent Plinabulin, is currently in multiple global registration studies, for the prevention of chemotherapy-induced neutropenia and as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company also has a robust internal early-stage pipeline, and a research collaboration with Fred Hutchinson Cancer Research Center and University of Washington exploring the ubiquitin ligase protein to target and promote the destruction of disease causing proteins, such as oncogenes.

Led by a highly qualified management team with proven pharmaceutical experience and a combined 30+ drugs brought to market, and a unique, highly scalable business model that integrates clinical resources in the U.S. and China, BeyondSpring believes that it is well positioned for expeditious progress towards regulatory approvals and commercialization in a cost-efficient manner.

## Primary IR Contact

Laura Perry / Joe Rayne

Argot Partners

**Phone:** 212.600.1902


**E-mail:**

[BeyondSpring@argotpartners.com](mailto:BeyondSpring@argotpartners.com)

## Stock Information

### BYSI (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$19.89</b>
Change (%)	▲ 0.04 (0.20%)
Volume	2,224
52 Week Low	\$19.00
Market Cap	\$446,643,913
Rolling EPS	-2.70
PE Ratio	0
Shares Outstanding	22,455,702



## Recent Press Releases & Upcoming Events

October 19, 2018

[BeyondSpring to Host Second-Quarter 2018 Financial](#)

[Results and Operational Update Conference Call on](#)

[October 23, 2018](#)

October 16, 2018

[BeyondSpring's Lead Asset, Plinabulin, Prevents Docetaxel](#)

[Chemo-Induced-Neutropenia \(CIN\) Due to a Mechanism of](#)

[Action Differentiated from G-CSF](#)

October 4, 2018

[Study Opens of BeyondSpring's Lead Asset, Plinabulin, and](#)

[Nivolumab + Ipilimumab in Small-Cell Lung Cancer](#)

Date	Title
October 22, 2018 4:30 p.m. CET	<a href="#"><u><b>BeyondSpring at European Society for Medical Oncology (ESMO) 2018 Congress</b></u></a>
October 23, 2018 8:00 a.m. ET	<a href="#"><u><b>BeyondSpring Second-Quarter 2018 Financial Results and Operational Update Conference Call</b></u></a>
November 9, 2018 12:45 p.m. ET	<a href="#"><u><b>BeyondSpring at Annual Meeting of the Society for Immunotherapy of Cancer (SITC)</b></u></a>

## SEC Filings

Filing Date	Form
August 1, 2018	<a href="#"><u>6-K</u></a>
June 21, 2018	<a href="#"><u>6-K</u></a>
May 30, 2018	<a href="#"><u>6-K</u></a>
May 29, 2018	<a href="#"><u>424B5</u></a>

## Corporate Governance

<a href="#"><u>Lan Huang, Ph.D.</u></a>	Co-founder, Chairman & CEO
<a href="#"><u>Ramon Mohanlal, M.D., Ph.D.</u></a>	Chief Medical Officer
<a href="#"><u>Edward Dongheng Liu</u></a>	Chief Financial Officer
<a href="#"><u>G. Kenneth Lloyd, Ph.D.</u></a>	Chief Scientific Officer
<a href="#"><u>Gordon L. Schooley, Ph.D.</u></a>	Chief Regulatory Officer